Literature DB >> 2348489

Clinical studies on bladder tumor-associated antigen in serum of patients with bladder cancer by using monoclonal antibody and sandwich ELISA.

S S Zhu1, Y C Zhang, R Z Hu, Z Q Ye, C J Li, Q A Lin.   

Abstract

Investigations on tumor-associated antigen in the serum of patients with bladder cancer by using monoclonal antibody Hb 7A and sandwich ELISA were carried out on 36 patients with bladder cancer (BCa group), 18 patients with other tissue tumor (OTT group) and 22 normal subjects (control group). The average OD value of Hb 7A antigen of BCa group, OTT group and control group was 0.315 +/- 0.033, 0.124 +/- 0.026 and 0.12 +/- 0.021 respectively. The OD value of Hb 7A antigen in BCa group was significantly higher than that of control group and of OTT group (P less than 0.01), but there was no obvious difference between the control group and OTT group (P greater than 0.05). The positive detection rate in BCa group was 86% (31/36), while detection in all 22 normal subjects and the 18 patients of OTT group yielded negative results. The results indicated that the method of using McAb Hb 7A and sandwich ELISA, characterized by high specificity and sensitivity, is of value for clinical diagnosis and follow-up of patients with bladder cancer and general survey of persons at high risk of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2348489     DOI: 10.1007/bf02909122

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  9 in total

Review 1.  Monoclonal antibodies: state of the art.

Authors:  N H Bander
Journal:  J Urol       Date:  1987-04       Impact factor: 7.450

Review 2.  Flow cytometry of the urinary bladder.

Authors:  M R Melamed
Journal:  Urol Clin North Am       Date:  1984-11       Impact factor: 2.241

3.  Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.

Authors:  G R Prout; W W Koontz; L J Coombs; I R Hawkins; G H Friedell
Journal:  J Urol       Date:  1983-10       Impact factor: 7.450

4.  Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing.

Authors:  D K Chopin; J B deKernion; D L Rosenthal; J L Fahey
Journal:  J Urol       Date:  1985-08       Impact factor: 7.450

5.  Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.

Authors:  H Huland; U Otto; M Droese; G Klöppel
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

6.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

7.  Detection of onco-fetal bladder antigen in urine of patients with transitional cell carcinoma.

Authors:  B C Liu; H Neuwirth; L W Zhu; L M Stock; J B Dekernion; J L Fahey
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

8.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

9.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.